MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate several intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Primary demo targets were being To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when one of many exploratory https://alexislpuxa.theblogfairy.com/30239472/the-fact-about-p-gb-in-1-that-no-one-is-suggesting